As Testosterone Treatment Lawsuit Filings Grow, Bernstein Liebhard LLP Notes Release of Study Questioning Accuracy of Testosterone Testing

Share Article

The publication of the study comes as federal regulators, as well as a growing number of testosterone lawsuit plaintiffs, voice concerns about the cardiovascular side effects potentially associated with the use of testosterone replacement therapy.

Free Case Review
The publication of this study comes as federal regulators, as well as a growing number of testosterone lawsuit plaintiffs, question the safety of these medications.

As testosterone treatment lawsuit (http://www.testosteronelawsuithub.com/) filings continue to grow in U.S. courts, Bernstein Liebhard LLP notes the release of a new study that raises questions about the accuracy of tests used to determine whether or not a man suffers from low levels of the hormone. The research, which was published on November 10th in The Journal of Sexual Medicine, drew on data collected from 320,000 men, ages 18 to 85, between the years of 2009 and 2012. During the study period, the proportion of men subjected to testosterone testing grew from 2.5% to 3.6%, something its authors attributed to the aggressive direct-to-consumer marketing of testosterone replacement drugs. However, only 9% of those tested had blood samples taken in the morning, which is considered optimum. As such, the authors of the study surmised that as many as 90% of the tested subjects did not receive accurate results.*

“The publication of this study comes as federal regulators, as well as a growing number of testosterone lawsuit plaintiffs, question the safety of these medications. In addition to their potential cardiovascular risk, some of these questions center on whether or not all of the men using the drugs have a true medical need for low testosterone therapy,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating legal claims on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other life-threatening heart problems due to their use of prescription testosterone medications.

Testosterone Litigation
Testosterone medications, such as AndroGel, Axiron, and Testim, are only approved for use in men who suffer from hypogonadism (low testosterone) due to an underlying medical condition or injury. In January, Food & Drug Administration (FDA) announced it was investigating the cardiovascular risks associated with low testosterone therapy. Since then, a panel of FDA advisors recommended that the drugs’ labels be revised to make clear they have not been shown to lessen low libido, fatigue, muscle loss and other age-related symptoms. They also recommended that the manufacturers of testosterone replacement therapies be required to conduct studies of their cardiovascular side effects.**

According to court documents, nearly 260 testosterone treatment lawsuits are now pending in a federal multidistrict litigation underway in U.S. District Court, Northern District of Illinois, all of which allege the medications are associated with an increased risk of heart attack, stroke and other life-threatening cardiovascular events. Among other things, the complaints claim that the manufacturers of low testosterone therapies failed to warn doctors and patients about their potential risks, and concealed those dangers from the public. The lawsuits further allege that sales of testosterone replacement products were driven by deceptive marketing tactics that induced many healthy men to use the drugs in the absence of a true medical need. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Men who allegedly suffered serious heart side effects due to their use of prescription testosterone therapies may be entitled to join this growing litigation. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.

*onlinelibrary.wiley.com/doi/10.1111/jsm.12730/abstract, The Journal of Sexual Health, November 10, 2014
**reuters.com/article/2014/09/17/us-usa-health-testosterone-idUSKBN0HC2C320140917, Reuters, September 18, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuithub.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website